Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 6, 2003, Pages 491-505

  Miller, Raymond ^a   Frame, Bill ^a   Corrigan, Brian ^a   Burger, Paula ^a   Bockbrader, Howard ^a   Garofalo, Elizabeth ^a   Lalonde, Richard ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; FEMALE; FOCAL EPILEPSY; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; META ANALYSIS; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OUTCOMES RESEARCH; PHARMACODYNAMICS; POISSON DISTRIBUTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; ALGORITHM; BIOLOGICAL MODEL; DRUG RESISTANCE; METHODOLOGY; POPULATION; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MODELS, BIOLOGICAL; POISSON DISTRIBUTION; POPULATION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0037534022     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00049-3     Document Type: Article

References (26)

1. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
2. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36.
3. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280: 107-10.
4. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93.
5. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-6.
6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth EILAT conference (EILAT IV). Epilepsy Res 1999;34:1-41.
7. Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock. Epilepsia 1997;38(Suppl 8):35 [abstract].
8. Taylor CP, Vartanian MG, Yuen PW, Bigge C, Suman-Chauhan N, Hill DR. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res 1993;14:11-5.
9. Taylor CP, Vartanian MG. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia 1997;38(Suppl 8):35 [abstract].
10. Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000;55(Suppl 3):S17-24.
11. Hopkins A, Davies P, Dobson S. Mathematical models of patterns of seizures: their use in the evaluation of drugs. Arch Neurol 1985;42:463-7.
12. Bruni J. Gabapentin as adjunctive therapy for partial seizures. Epilepsia 1999;40(Suppl 6):S27-8.
13. Cramer JA, French J. Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components. Epilepsia 2001;42:119-29.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Beal SL, Sheiner LB, editors. NONMEM user's guides. NONMEM Project Group. San Francisco: University of California at San Francisco; 1992.
16. Efron B, Tibshirani RJ. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54-77.
17. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-95.
18. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001;28: 171-92.
19. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68:677-87.
20. Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB. A population pharmacokinetic/pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of Ondanstron. J Pharmacokinet Pharmacodyn 1999;27: 625-44.
21. Bockbrader HN, Burger PJ, Corrigan BW, Kugler AR, Knapp LE, Garofalo, EA, et al. Population pharmacokinetic (PK) analysis of pregabalin (PG) in adult patients with refractory partial seizures [abstract]. Epilepsia 2001; 42(Suppl 7):84.
22. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-74.
23. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
24. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001;42(Suppl 3): 27-30.
25. Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 2000;42(Suppl 3):31-5.
26. McLachlan GJ, Basford KE. Mixture models - inference and applications to clustering. New York: Marcel Dekker; 1988.